Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes

作者
Meredith M. Hoog,Carlos R. Vallarino,Juan M. Maldonado,Michael Grabner,Chia‐Chen Teng,Kendra A. Terrell,Emma L. Richard
出处
期刊:Diabetes Therapy [Adis, Springer Healthcare]
卷期号:16 (11): 2237-2256 被引量:8
标识
DOI:10.1007/s13300-025-01794-9
摘要

To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management. This retrospective analysis utilized the Healthcare Integrated Research Database® to identify adults with T2D starting tirzepatide or injectable semaglutide between May 13, 2022 and May 29, 2023. GLP-1 RA naïve and non-naïve cohorts were identified based on the history of GLP-1 RA use within ≤ 6 months of initiation. Propensity score matching balanced 6-month baseline characteristics between groups. HbA1c and weight changes were assessed from initiation to 12 months for matched patients with HbA1c and weight data at both time points. Both matched naïve cohorts were comprised of 10,702 patients (tirzepatide: 1399 with HbA1c data and 454 with weight data; semaglutide: 1173 with HbA1c data and 432 with weight data). Mean baseline HbA1c and weight were 7.8% and 112.4 kg, respectively, for the tirzepatide group and 7.8% and 110.7 kg for the semaglutide group. Both matched non-naïve cohorts were comprised of 5577 patients (tirzepatide: 792 with HbA1c data and 296 with weight data; semaglutide: 738 with HbA1c data and 224 with weight data). Mean baseline HbA1c and weight were 7.7% and 112.5 kg for tirzepatide, and 7.9% and 108.5 kg for semaglutide. Tirzepatide was associated with greater mean reductions in HbA1c (naïve: – 1.3% vs. – 0.9%; non-naïve: – 0.9% vs. – 0.6%; p < 0.001) and weight (naïve: – 10.2 kg vs. – 6.1 kg; non-naïve: – 7.9 kg vs. – 3.7 kg; p < 0.001) than semaglutide. Patients with T2D starting tirzepatide had greater HbA1c and weight reductions at 12 months post-initiation than those on injectable semaglutide, regardless of previous GLP-1 RA use, consistent with previous clinical trial results. Type 2 diabetes (T2D) is a serious health issue, often linked to other health conditions like obesity. There is little information on the real-world effects of tirzepatide (a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1]) compared to semaglutide (a GLP-1 receptor agonist only) in helping people with type 2 diabetes improve their blood sugar control (HbA1c) and lose weight. This study used real-world data from the Healthcare Integrated Research Database (HIRD®), including adults with T2D who initiated either tirzepatide (Mounjaro®) or semaglutide (Ozempic®). Patients with and without past use of GLP-1 receptor agonists were looked at separately. HbA1c and weight were measured at the start of treatment (baseline) and again after 12 months. After 12 months, people who initiated tirzepatide achieved lower HbA1c levels and lost more weight than those who initiated semaglutide. Among GLP-1 naïve patients, tirzepatide users reduced their HbA1c by 1.3% and lost 10.2 kg, while semaglutide users reduced their HbA1c by 0.9% and lost 6.1 kg, on average. Tirzepatide was also more effective at reducing HbA1c and weight than semaglutide among people with prior GLP-1 receptor agonist use. Clinical trials show how well and how safely medicines work in controlled settings. Once available for use in routine medical practice, real-world studies give additional information about how the medicines work in everyday medical care. This analysis compares two approved medicines used to treat T2D in real life and may help doctors and health leaders make decisions to improve care for people with this condition.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小彭陪小崔读个研完成签到 ,获得积分10
1秒前
黄毛虎发布了新的文献求助10
1秒前
憨包完成签到 ,获得积分10
2秒前
lx完成签到,获得积分10
2秒前
CodeCraft的应助被学术超女采纳,获得10
2秒前
快乐曼荷完成签到,获得积分10
3秒前
3秒前
11完成签到,获得积分10
4秒前
w7完成签到 ,获得积分10
5秒前
5秒前
简单静丹完成签到,获得积分10
6秒前
无极微光的应助被薇子采纳,获得20
6秒前
尊嘟假嘟发布了新的文献求助10
6秒前
满意的醉蝶完成签到,获得积分10
7秒前
Alin完成签到,获得积分10
7秒前
8秒前
马世杰发布了新的文献求助20
8秒前
隐形听白完成签到,获得积分10
8秒前
尊嘟假嘟发布了新的文献求助10
8秒前
8秒前
尊嘟假嘟发布了新的文献求助10
10秒前
书篆完成签到,获得积分10
10秒前
富士山下完成签到,获得积分20
11秒前
KFY发布了新的文献求助10
12秒前
默默向雪完成签到,获得积分10
12秒前
尊嘟假嘟发布了新的文献求助10
12秒前
尊嘟假嘟发布了新的文献求助10
12秒前
尊嘟假嘟发布了新的文献求助10
12秒前
研研研究不出完成签到,获得积分10
12秒前
ssy发布了新的文献求助10
13秒前
August完成签到,获得积分10
13秒前
田様的应助被豆包采纳,获得10
13秒前
尊嘟假嘟发布了新的文献求助10
13秒前
14秒前
tiantian完成签到 ,获得积分10
14秒前
科研66666发布了新的文献求助10
15秒前
人间慈悲的应助被甜甜甜采纳,获得10
15秒前
16秒前
尊嘟假嘟发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186819
求助须知:如何正确求助?哪些是违规求助? 9575195
关于积分的说明 21839872
捐赠科研通 7784526
什么是DOI,文献DOI怎么找? 3434849
关于科研通互助平台的介绍 2559266
邀请新用户注册赠送积分活动 2481716